Market Summary
USD437.24+1.55
Market Closed0.36%
IDXX Stock Price
IDXX RSI Chart
IDXX Valuation
IDXX Price/Sales (Trailing)
IDXX Profitability
IDXX Fundamentals
IDXX Revenue
IDXX Earnings
Price Action
52 Week Range
317.06564.74
(Low)(High)
Last 7 days
-3.3%
Last 30 days
-13.4%
Last 90 days
-10.7%
Trailing 12 Months
33.6%
IDXX Financial Health
IDXX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for IDXX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-06 | AYERS JONATHAN W | gifted | - | - | -147,821 | - |
2023-09-06 | AYERS JONATHAN W | gifted | - | - | 147,821 | - |
2023-09-01 | Smith Martin Alexander | acquired | - | - | 19.00 | executive vice president |
2023-09-01 | AYERS JONATHAN W | gifted | - | - | -250 | - |
2023-09-01 | Smith Martin Alexander | sold (taxes) | -2,556 | 511 | -5.00 | executive vice president |
2023-08-31 | MAZELSKY JONATHAN JAY | acquired | 1,067,740 | 79.54 | 13,424 | president and ceo |
2023-08-31 | AYERS JONATHAN W | gifted | - | - | -1,250 | - |
2023-08-31 | MAZELSKY JONATHAN JAY | sold | -6,873,270 | 512 | -13,424 | president and ceo |
2023-08-29 | POLEWACZYK JAMES F | acquired | 2,438,480 | 144 | 16,909 | executive vice president |
2023-08-29 | POLEWACZYK JAMES F | sold | -11,696,400 | 510 | -22,909 | executive vice president |
Which funds bought or sold IDXX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Baystate Wealth Management LLC | added | 23.2 | 29,667 | 154,687 | 0.01% |
2023-09-21 | Jefferies Group LLC | new | - | 2,117,700 | 2,117,700 | 0.02% |
2023-09-20 | BARCLAYS PLC | added | 95.78 | 41,798,000 | 85,064,000 | 0.05% |
2023-09-14 | IMS Capital Management | reduced | -3.04 | -10,789 | 400,277 | 0.22% |
2023-09-12 | Farther Finance Advisors, LLC | added | 4.17 | 1,108 | 25,112 | -% |
2023-09-07 | ACADEMY CAPITAL MANAGEMENT INC/TX | reduced | -0.73 | -53,519 | 17,562,500 | 3.52% |
2023-09-07 | JAG CAPITAL MANAGEMENT, LLC | added | 3.43 | 131,637 | 3,531,680 | 0.41% |
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | 2.00 | 503 | -% |
2023-08-30 | Western Wealth Management, LLC | unchanged | - | 4,684 | 1,094,360 | 0.09% |
2023-08-29 | Garde Capital, Inc. | unchanged | - | 1,000 | 309,000 | 0.03% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of IDEXX Laboratories
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | fundsmith llp | 5.37% | 4,447,828 | SC 13G | |
| Feb 14, 2023 | fundsmith llp | 5.37% | 4,447,828 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 9.82% | 8,132,479 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 10.3% | 8,502,881 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 10.3% | 8,502,881 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 9.34% | 7,923,466 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 10.6% | 8,990,586 | SC 13G/A | |
| Jan 25, 2022 | blackrock inc. | 10.6% | 8,990,586 | SC 13G/A | |
| Sep 09, 2021 | blackrock inc. | 10.1% | 8,612,405 | SC 13G/A | |
| Feb 12, 2021 | fundsmith llp | 4.95% | 4,226,428 | SC 13G/A |
Recent SEC filings of IDEXX Laboratories
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Aug 31, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 31, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 17, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 4 | Insider Trading |
Peers (Alternatives to IDEXX Laboratories)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 186.1B | 30.4B | -2.55% | -6.78% | 29.25 | 6.13 | -1.49% | 0.14% |
ABT | 169.6B | 40.2B | -6.64% | -2.43% | 32.87 | 4.22 | -11.68% | -39.67% |
MDT | 106.4B | 31.6B | -4.08% | -3.94% | 29.34 | 3.37 | 1.57% | -30.40% |
IDXX | 36.3B | 3.5B | -13.39% | 33.61% | 45.89 | 10.33 | 6.21% | 19.20% |
WST | 27.8B | 2.9B | -5.23% | 47.17% | 53.51 | 9.68 | -2.14% | -24.34% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -2.12% | 37.22% | 325.17 | 10.1 | 16.30% | 250.21% |
LNTH | 4.5B | 1.1B | -6.83% | -12.71% | 135.07 | 4.01 | 69.36% | 3.03% |
NEOG | 4.2B | 822.4M | -17.77% | 27.32% | -184 | 5.12 | 56.01% | -147.34% |
QDEL | - | - | -12.36% | -2.62% | - | - | - | - |
| SMALL-CAP | ||||||||
VIVO | 1.5B | 301.6M | 2.29% | 56.91% | -550.1 | 4.93 | -3.75% | -104.51% |
HSKA | 1.2B | 254.9M | 2.45% | 31.18% | -62.25 | 4.89 | -1.22% | 15.74% |
CYRX | 664.8M | 240.7M | -6.95% | -50.26% | -15.57 | 2.76 | 4.82% | 85.44% |
AWH | 43.3M | 9.0M | 56.07% | -12.11% | -2.4 | 4.79 | 20.81% | 50.13% |
QTNT | 766.7K | 37.4M | -50.00% | -99.61% | -0.01 | 0.02 | -2.49% | 10.49% |
IDEXX Laboratories News
Returns for IDXX
Cumulative Returns on IDXX
24.4%
10-Year Cumulative Returns
21.5%
7-Year Cumulative Returns
12.6%
5-Year Cumulative Returns
5.8%
3-Year Cumulative Returns
Risks for IDXX
What is the probability of a big loss on IDXX?
68.8%
Probability that IDEXX Laboratories stock will be more than 20% underwater in next one year
38.5%
Probability that IDEXX Laboratories stock will be more than 30% underwater in next one year.
18.5%
Probability that IDEXX Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does IDXX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if IDEXX Laboratories was unfortunately bought at previous high price.
Drawdowns
Financials for IDEXX Laboratories
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.4% | 3,514 | 3,431 | 3,367 | 3,340 | 3,309 | 3,274 | 3,215 | 3,135 | 3,047 | 2,858 | 2,707 | 2,591 | 2,475 | 2,457 | 2,407 | 2,351 | 2,291 | 2,252 | 2,213 | 2,170 | 2,117 |
| Cost Of Revenue | 1.8% | 1,407 | 1,382 | 1,363 | 1,364 | 1,366 | 1,357 | 1,326 | 1,308 | 1,288 | 1,228 | 1,136 | - | - | - | 1,041 | - | - | - | 972 | 956 | 934 |
| Gross Profit | 2.9% | 2,107 | 2,049 | 2,004 | 1,976 | 1,942 | 1,917 | 1,889 | 1,843 | 1,792 | 1,682 | 1,571 | 1,493 | 1,415 | 1,394 | 1,366 | 1,335 | 1,295 | 1,270 | 1,242 | 1,214 | 1,182 |
| S&GA Expenses | 1.9% | 550 | 540 | 525 | 521 | 515 | 504 | 487 | 474 | 458 | 433 | 434 | 424 | 421 | 428 | 418 | 408 | 399 | 394 | 387 | 382 | 376 |
| R&D Expenses | -29.6% | 183 | 259 | 255 | 257 | 249 | 164 | 161 | 154 | 152 | 146 | 141 | 138 | 134 | 135 | 133 | 128 | 123 | 120 | 118 | 117 | 115 |
| EBITDA | -100.0% | - | 1,046 | 1,012 | 983 | 962 | 1,039 | 1,037 | 1,020 | 964 | 896 | 791 | 720 | 685 | 654 | 641 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.30* | 0.30* | 0.29* | 0.29* | 0.32* | 0.32* | 0.33* | 0.32* | 0.31* | 0.29* | 0.28* | 0.28* | 0.27* | 0.27* | - | - | - | - | - | - |
| Interest Expenses | 4.8% | 48.00 | 46.00 | 40.00 | 34.00 | 30.00 | 29.00 | 30.00 | 30.00 | 31.00 | 33.00 | 33.00 | 33.00 | 32.00 | 30.00 | 31.00 | 32.00 | 34.00 | 34.00 | 35.00 | 36.00 | 37.00 |
| Earnings Before Taxes | 13.0% | 1,001 | 886 | 860 | 839 | 823 | 904 | 903 | 888 | 833 | 765 | 662 | 593 | 562 | 534 | 522 | 521 | 497 | 478 | 458 | 440 | 423 |
| EBT Margin | -100.0% | - | 0.26* | 0.26* | 0.25* | 0.25* | 0.28* | 0.28* | 0.28* | 0.27* | 0.27* | 0.24* | 0.23* | 0.23* | 0.22* | 0.22* | - | - | - | - | - | - |
| Net Income | 13.2% | 791 | 699 | 679 | 670 | 664 | 735 | 745 | 757 | 728 | 674 | 582 | 498 | 460 | 437 | 428 | 423 | 407 | 390 | 377 | 330 | 307 |
| Net Income Margin | -100.0% | - | 0.20* | 0.20* | 0.20* | 0.20* | 0.22* | 0.23* | 0.24* | 0.24* | 0.24* | 0.21* | 0.19* | 0.19* | 0.18* | 0.18* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 456 | 394 | 448 | 439 | 615 | 636 | 663 | 694 | 666 | 541 | 446 | 367 | 287 | 304 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 2.2% | 2,871 | 2,808 | 2,747 | 2,640 | 2,607 | 2,593 | 2,437 | 2,386 | 2,412 | 2,327 | 2,295 | 2,047 | 1,961 | 1,886 | 1,832 | 1,751 | 1,724 | 1,681 | 1,537 | 1,545 | 1,521 |
| Current Assets | 2.6% | 1,179 | 1,149 | 1,101 | 1,059 | 1,043 | 1,090 | 956 | 938 | 1,001 | 1,098 | 1,063 | 869 | 780 | 721 | 680 | 703 | 712 | 698 | 654 | 704 | 740 |
| Cash Equivalents | 19.3% | 133 | 111 | 113 | 99.00 | 114 | 205 | 144 | 145 | 232 | 351 | 384 | 176 | 105 | 81.00 | 90.00 | 104 | 111 | 117 | 124 | 147 | 175 |
| Inventory | 1.1% | 395 | 391 | 368 | 355 | 333 | 302 | 269 | 258 | 241 | 226 | 210 | 218 | 229 | 212 | 195 | 205 | 197 | 189 | 173 | 180 | 176 |
| Net PPE | 2.7% | 683 | 665 | 649 | 612 | 594 | 593 | 588 | 573 | 550 | 544 | 555 | 548 | 551 | 546 | 534 | 497 | 470 | 449 | 437 | 410 | 394 |
| Goodwill | 0.3% | 364 | 363 | 362 | 355 | 356 | 361 | 359 | 4.00 | 109 | 243 | 243 | 238 | 235 | 23.00 | 240 | 25.00 | 215 | 215 | 214 | 20.00 | 196 |
| Liabilities | -9.7% | 1,777 | 1,967 | 2,138 | 2,164 | 2,150 | 1,953 | 1,747 | 1,630 | 1,664 | 1,624 | 1,662 | 1,606 | 1,687 | 1,778 | 1,655 | 1,549 | 1,553 | 1,629 | 1,629 | 1,546 | 1,562 |
| Current Liabilities | -17.1% | 884 | 1,066 | 1,236 | 1,190 | 1,167 | 971 | 764 | 634 | 652 | 621 | 583 | 527 | 541 | 846 | 725 | 627 | 619 | 690 | 770 | 760 | 774 |
| LT Debt, Current | 0.0% | 75.00 | 75.00 | 75.00 | - | - | - | 75.00 | 75.00 | 125 | 125 | 50.00 | 50.00 | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | 0.1% | 697 | 696 | 694 | 761 | 768 | 773 | 775 | 778 | 780 | 779 | 858 | 853 | - | - | 699 | - | - | - | - | - | - |
| Shareholder's Equity | 30.1% | 1,094 | 841 | 609 | 476 | 457 | 640 | 690 | 755 | 748 | 703 | 633 | 441 | 273 | 108 | 178 | 203 | 172 | 52.00 | - | - | - |
| Retained Earnings | 5.9% | 4,038 | 3,814 | 3,600 | 3,427 | 3,246 | 3,114 | 2,920 | 2,758 | 2,582 | 2,380 | 2,176 | 2,001 | 1,855 | 1,706 | 1,596 | 1,505 | 1,396 | 1,271 | 1,168 | 1,082 | 989 |
| Additional Paid-In Capital | 1.7% | 1,515 | 1,490 | 1,463 | 1,438 | 1,420 | 1,400 | 1,377 | 1,359 | 1,339 | 1,321 | 1,295 | 1,274 | 1,247 | 1,230 | 1,214 | 1,190 | 1,171 | 1,156 | 1,138 | 1,128 | 1,109 |
| Shares Outstanding | 0.1% | 83.00 | 83.00 | 83.00 | 83.00 | 84.00 | 84.00 | 85.00 | 85.00 | 85.00 | 86.00 | 85.00 | 85.00 | 85.00 | 85.00 | 85.00 | 86.00 | 86.00 | 86.00 | 86.00 | 87.00 | 87.00 |
| Minority Interest | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 22.0% | 747 | 612 | 543 | 580 | 578 | 746 | 756 | 765 | 770 | 745 | 648 | 585 | 524 | 453 | 459 | 439 | 418 | 400 | 400 | 386 | 386 |
| Share Based Compensation | 5.7% | 56.00 | 53.00 | 50.00 | 46.00 | 43.00 | 40.00 | 38.00 | 36.00 | 34.00 | 33.00 | 31.00 | 40.00 | 41.00 | 40.00 | 39.00 | 29.00 | 26.00 | 26.00 | 25.00 | 25.00 | 24.00 |
| Cashflow From Investing | 14.3% | -165 | -193 | -195 | -190 | -190 | -310 | -292 | -264 | -234 | -84.29 | -109 | -189 | -207 | -216 | -205 | -149 | -166 | -159 | 139 | 154 | 167 |
| Cashflow From Financing | -11.7% | -562 | -503 | -370 | -420 | -492 | -581 | -697 | -531 | -413 | -394 | -248 | -323 | -318 | -266 | -286 | -329 | -314 | -275 | -597 | -558 | -541 |
| Buy Backs | -55.4% | 247 | 553 | 820 | 990 | 999 | 881 | 747 | 502 | 321 | 132 | 183 | 324 | 409 | 430 | 302 | 267 | 254 | 340 | 369 | 318 | 302 |
IDXX Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 943,630 | $ 860,546 | $ 1,843,825 | $ 1,697,095 |
| Cost of Revenue: | ||||
| Cost of revenue | 370,780 | 346,514 | 728,004 | 684,310 |
| Gross profit | 572,850 | 514,032 | 1,115,821 | 1,012,785 |
| Expenses: | ||||
| Sales and marketing | 140,532 | 130,257 | 288,336 | 262,549 |
| General and administrative | 89,669 | 81,488 | 159,770 | 159,437 |
| Research and development | 46,505 | 123,221 | 91,172 | 163,389 |
| Income from operations | 296,144 | 179,066 | 576,543 | 427,410 |
| Interest expense | (10,542) | (8,317) | (23,669) | (15,313) |
| Interest income | 327 | 334 | 743 | 477 |
| Income before provision for income taxes | 285,929 | 171,083 | 553,617 | 412,574 |
| Provision for income taxes | 61,693 | 39,104 | 115,327 | 86,630 |
| Net income attributable to IDEXX Laboratories, Inc. stockholders | $ 224,236 | $ 131,979 | $ 438,290 | $ 325,944 |
| Earnings per Share: | ||||
| Basic (in USD per share) | $ 2.70 | $ 1.57 | $ 5.28 | $ 3.87 |
| Diluted (in USD per share) | $ 2.67 | $ 1.56 | $ 5.22 | $ 3.82 |
| Weighted Average Shares Outstanding: | ||||
| Basic (in shares) | 83,086 | 83,922 | 83,039 | 84,164 |
| Diluted (in shares) | 83,983 | 84,858 | 83,980 | 85,222 |
| Product revenue | ||||
| Revenue: | ||||
| Total revenue | $ 540,680 | $ 492,518 | $ 1,046,622 | $ 970,895 |
| Cost of Revenue: | ||||
| Cost of revenue | 179,999 | 167,323 | 353,609 | 329,394 |
| Service revenue | ||||
| Revenue: | ||||
| Total revenue | 402,950 | 368,028 | 797,203 | 726,200 |
| Cost of Revenue: | ||||
| Cost of revenue | $ 190,781 | $ 179,191 | $ 374,395 | $ 354,916 |
IDXX Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 132,838 | $ 112,546 |
| Accounts receivable, net | 461,858 | 400,619 |
| Inventories | 395,141 | 367,823 |
| Other current assets | 189,188 | 220,489 |
| Total current assets | 1,179,025 | 1,101,477 |
| Long-Term Assets: | ||
| Property and equipment, net | 683,270 | 649,474 |
| Operating lease right-of-use assets | 114,148 | 118,618 |
| Goodwill | 364,206 | 361,795 |
| Intangible assets, net | 90,932 | 97,672 |
| Other long-term assets | 439,225 | 417,729 |
| Total long-term assets | 1,691,781 | 1,645,288 |
| TOTAL ASSETS | 2,870,806 | 2,746,765 |
| Current Liabilities: | ||
| Accounts payable | 107,664 | 110,221 |
| Accrued liabilities | 399,425 | 433,662 |
| Credit facility | 264,000 | 579,000 |
| Current portion of long-term debt | 74,991 | 74,982 |
| Current portion of deferred revenue | 37,779 | 37,938 |
| Total current liabilities | 883,859 | 1,235,803 |
| Long-Term Liabilities: | ||
| Deferred income tax liabilities | 5,568 | 8,150 |
| Long-term debt, net of current portion | 696,844 | 694,387 |
| Long-term deferred revenue, net of current portion | 29,054 | 30,862 |
| Long-term operating lease liabilities | 97,337 | 101,239 |
| Other long-term liabilities | 64,283 | 67,587 |
| Total long-term liabilities | 893,086 | 902,225 |
| Total liabilities | 1,776,945 | 2,138,028 |
| Commitments and Contingencies (Note 16) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,378 shares in 2023 and 107,193 shares in 2022; Outstanding: 83,060 shares in 2023 and 82,894 shares in 2022 | 10,738 | 10,719 |
| Additional paid-in capital | 1,515,197 | 1,463,215 |
| Deferred stock units: Outstanding: 59 units in 2023 and 58 units in 2022 | 5,515 | 5,182 |
| Retained earnings | 4,037,819 | 3,599,529 |
| Accumulated other comprehensive loss | (73,665) | (77,796) |
| Treasury stock, at cost: 24,318 shares in 2023 and 24,299 shares in 2022 | (4,401,743) | (4,392,112) |
| Total stockholders’ equity | 1,093,861 | 608,737 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 2,870,806 | $ 2,746,765 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.